My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT nasdaq
United States
Sarepta Therapeutics

Sarepta Therapeutics Stock Analysis & Ratings

Sarepta Therapeutics Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Sarepta Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

SRPT

SRPT Stock Stats

Previous Close$84.19
Open$84.1
Bid75 x 1
Ask83 x 29
Today’s Range$79.88 - $84.81
52-Week Range$65.30 - $181.83
Volume2.16M
Average Volume910.04K
Market Cap$6.48B
Beta1.42
P/E Ratio-10.5
EPS-8.03
Earnings DateOct 27, 2021

Company Description

Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
Douglas S. Ingram
Employees
866
ISIN
US8036071004
Address
215 First Street, Cambridge, MA, 02142, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

SRPT FAQ

What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $65.30 and its highest was $181.83 in the past 12 months.
    What is Sarepta Therapeutics’s market cap?
    Sarepta Therapeutics’s market cap is $6.48B.
      What is Sarepta Therapeutics’s price target?
      The average price target for Sarepta Therapeutics is $119.30. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $166.00 ,the lowest forecast is $87.00. The average price target represents 46.89% Increase from the current price of $81.22.
        What do analysts say about Sarepta Therapeutics?
        Sarepta Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
          When is Sarepta Therapeutics’s upcoming earnings report date?
          Sarepta Therapeutics’s upcoming earnings report date is Oct 27, 2021 which is in 8 days.
            How were Sarepta Therapeutics’s earnings last quarter?
            Sarepta Therapeutics released its earnings results on Aug 04, 2021. The company reported -$1.021 earnings per share for the quarter, beating the consensus estimate of -$1.298 by $0.277.
              Is Sarepta Therapeutics overvalued?
              According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
                Does Sarepta Therapeutics pay dividends?
                Sarepta Therapeutics does not currently pay dividends.
                What is Sarepta Therapeutics’s EPS estimate?
                Sarepta Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Sarepta Therapeutics have?
                Sarepta Therapeutics has 79,840,000 shares outstanding.
                  What happened to Sarepta Therapeutics’s price movement after its last earnings report?
                  Sarepta Therapeutics reported an EPS of -$1.021 in its last earnings report, beating expectations of -$1.298. Following the earnings report the stock price went up 13.76%.
                    Which hedge fund is a major shareholder of Sarepta Therapeutics?
                    Among the largest hedge funds holding Sarepta Therapeutics’s share is Sands Capital Management LLC. It holds Sarepta Therapeutics’s shares valued at 436M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis